Form 4: Ocuphire Pharma Director Jay Pepose Reports Stock and Option Grants

Director Jay Pepose reports receiving restricted stock units and stock options from Ocuphire Pharma.

Summary

• On June 11, 2024, Jay Pepose, a director of Ocuphire Pharma, Inc., reported transactions involving the company's securities.
• Pepose acquired 41,143 shares of common stock through a grant of restricted stock units.
• He also acquired options to purchase 35,181 shares of common stock at an exercise price of $1.72.
• The restricted stock units and options vest upon the earlier of the one-year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continued service.
• Following these transactions, Pepose beneficially owns 180,458 shares of common stock and options for 35,181 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard equity grant, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of restricted stock units and options aligns the director's interests with those of the shareholders.
• The vesting conditions incentivize continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This type of equity grant is a common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Equity compensation for board members in biotech companies typically includes a mix of stock options and restricted stock units.
• The vesting schedules are generally aligned with industry standards, often contingent on continued service and performance milestones.
• The size of the grant is likely benchmarked against peer companies of similar market capitalization and stage of development.

Stakeholder Impact

• Shareholders may view the equity grant positively as it incentivizes the director to work towards increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates